Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes

American Heart Journal

Volumn 147, Issue 2, 2004, Pages 246-252

  McGuire, Darren K ^a   Newby, L Kristin ^b   Bhapkar, Manjushri V ^b   Moliterno, David J ^c   Hochman, Judith S ^d   Klein, Werner W ^e   Weaver, W Douglas ^f   Pfisterer, Matthias ^g   Corbalán, Ramón ^h   Dellborg, Mikael ⁱ   Granger, Christopher B ^b   Van De Werf, Frans ^j   Topol, Eric J ^c   Califf, Robert M ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY HOSPITAL GRAZ   (Austria)

^f HENRY FORD HOSPITAL   (United States)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; INSULIN; SULFONYLUREA;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SEX DIFFERENCE; SMOKING HABIT; TREATMENT PLANNING;

EID: 10744231601     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.07.024     Document Type: Article

References (26)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
2. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014-9.
3. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
4. McGuire DK, Emanuelsson H, Granger CB, et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes: findings from the GUSTO-IIb study: GUSTO IIb Investigators. Eur Heart J 2000;21:1750-8.
5. Bypass Angioplasty Revascularization Investigation 2: Diabetes (BARI 2D). Available at: http://www.edc.gsph.pitt.edu/bari2d/.
6. SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndrames: a randamised trial: the SYMPHONY Investigators: Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000;355: 337-45.
7. Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001;103:1727-33.
8. Newby LK. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial: Symphony Steering Committee. Am Heart J 1999;138:210-8.
9. Newby LK, Bhapkar MV, White HD, et al. Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. Eur Heart J 2003;24:172-81.
10. Rao SV, Bethel MA, Feinglos MN. Treatment of diabetes mellitus: implications of the use of oral agents. Am Heart J 1999;138: S334-7.
11. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72.
12. Fleming A. FDA approach to the regulation of drugs for diabetes. Am Heart J 1999;138:S338-45.
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucase control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.
14. Raji A, Plutzky J. Insulin resistance, diabetes, and atherosclerosis: thiazalidinedianes as therapeutic interventions. Curr Cardiol Rep 2002;4:514-21.
15. Clevelond JC Jr, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revisited. Circulation 1997;96:29-32.
16. Sobel BE. The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes. Proc Assoc Am Physicians 1999;111:313-8.
17. Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003;290:81-5.
18. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, II: mortality results. Diabetes 1970;19(Suppl): 789-830.
19. Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial: Veterans Affairs Cooperative Study on Glycemic Control and Camplications in Type II Diabetes. Arch Intern Med 1997;157:181-8.
20. Abraira C, Duckworth WC, McCarren M. Seven-year VA cooperative study on glycemic control and complications. Diabetes 2000; 49(Suppl):A1422.
21. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
22. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.
23. Hildebrandt PR, Snorgaard O, Melchior TM, et al. [Treatment of diabetic patients with ischaemic heart disease]. Ugeskr Laeger 2000;162:4125-8.
24. Fisman EZ, Tenenbaum A, Benderly M, et al. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 1999; 91:195-202.
25. Bypass Angioplasty Revascularization Investigation 2: Diabetes (BARI 2D). Available at: http://www.edc.gsph.pitt.edu/bari2d/.
26. Action to Control Cardiovascular Risk in Diabetes (ACCORD). Available at: http://www.niddk.nih.gov/health/diabetes/dateline/fall00/2.htm.